Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Degarelix Acetate

FDA-approved product (powder, subcutaneous), marketed as Firmagon.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Degarelix Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Prostate adenocarcinoma
  • Prostate cancer
  • Prostate carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other hormone antagonists and related agents
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA62.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli57.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae48.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis66.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Degarelix Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Degarelix Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

    NCT03070886 · start 2017-04-05

    Registered record
    Registry ID
    NCT03070886
    Conditions
    Stage I Prostate Adenocarcinoma AJCC v7; Stage II Prostate Adenocarcinoma AJCC v7; Stage III Prostate Adenocarcinoma AJCC v7
    Interventions
    Bicalutamide; Degarelix; Docetaxel; External Beam Radiation Therapy; Flutamide; Goserelin; Goserelin Acetate; Laboratory Biomarker Analysis; Leuprolide; Leuprolide Acetate; Nilutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Active not recruiting
    Start
    2017-04-05
    Completion
    2030-10-31
    Enrolment
    612

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStage I Prostate Adenocarcinoma AJCC v7; Stage II Prostate Adenocarcinoma AJCC v7; Stage III Prostate Adenocarcinoma AJCC v7
    InterventionBicalutamide; Degarelix; Docetaxel; External Beam Radiation Therapy +7 more
    PhasePhase 2 / Phase 3
    Registry statusActive not recruiting

  • A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy

    NCT02849990 · start 2017-03-09

    Registered record
    Registry ID
    NCT02849990
    Conditions
    Stage III Prostate Adenocarcinoma AJCC v7; Stage III Prostate Cancer AJCC v7; Stage IV Prostate Adenocarcinoma AJCC v7; Stage IV Prostate Cancer AJCC v7
    Interventions
    Abiraterone Acetate; Apalutamide; Degarelix; Indomethacin; Laboratory Biomarker Analysis; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-03-09
    Completion
    2020-12-10
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStage III Prostate Adenocarcinoma AJCC v7; Stage III Prostate Cancer AJCC v7; Stage IV Prostate Adenocarcinoma AJCC v7; Stage IV Prostate Cancer AJCC v7
    InterventionAbiraterone Acetate; Apalutamide; Degarelix; Indomethacin +2 more
    PhasePhase 2
    Registry statusCompleted

  • A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

    NCT03009981 · start 2017-03-06

    Registered record
    Registry ID
    NCT03009981
    Conditions
    Prostate Cancer
    Interventions
    Apalutamide; LHRH Analogue; Abiraterone Acetate; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-03-06
    Completion
    2025-06-25
    Enrolment
    504

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionApalutamide; LHRH Analogue; Abiraterone Acetate; Prednisone
    PhasePhase 3
    Registry statusCompleted

  • Real-life Evaluation of the Effect of ADT in Prostate Cancer Patients in Asia (READT Asia Study)

    NCT03703778 · start 2016-05-22

    Registered record
    Registry ID
    NCT03703778
    Conditions
    Prostate Cancer
    Interventions
    Androgen deprivation therapy - bilateral orchidectomy; Androgen deprivation therapy - GnRH agonist; Androgen deprivation therapy - GnRH antagonist
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2016-05-22
    Completion
    2026-03-31
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionAndrogen deprivation therapy - bilateral orchidectomy; Androgen deprivation therapy - GnRH agonist; Androgen deprivation therapy - GnRH antagonist
    PhaseNot recorded
    Registry statusActive not recruiting

  • Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer

    NCT02278185 · start 2015-11-11

    Registered record
    Registry ID
    NCT02278185
    Conditions
    Adenocarcinoma of the Prostate; Recurrent Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer
    Interventions
    Enzalutamide; leuprolide acetate; goserelin acetate; histrelin acetate; triptorelin; degarelix
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-11-11
    Completion
    2024-07-18
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenocarcinoma of the Prostate; Recurrent Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer
    InterventionEnzalutamide; leuprolide acetate; goserelin acetate; histrelin acetate +2 more
    PhasePhase 2
    Registry statusCompleted

  • Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer

    NCT02494713 · start 2015-10

    Registered record
    Registry ID
    NCT02494713
    Conditions
    Prostate Cancer
    Interventions
    Degarelix; Doxorubicin; Ketoconazole; Docetaxel; Estramustine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2015-10
    Completion
    2017-09-14
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionDegarelix; Doxorubicin; Ketoconazole; Docetaxel +1 more
    PhasePhase 2
    Registry statusTerminated

  • High-Dose Brachytherapy in Treating Patients With Prostate Cancer

    NCT02346253 · start 2015-01-13

    Registered record
    Registry ID
    NCT02346253
    Conditions
    Prostate Adenocarcinoma; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer
    Interventions
    Internal Radiation Therapy; Bicalutamide; Leuprolide Acetate; Goserelin Acetate; Triptorelin Pamoate; Degarelix; Laboratory Biomarker Analysis; Quality-of-Life Assessment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-01-13
    Completion
    2026-05-17
    Enrolment
    146

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Adenocarcinoma; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer +1 more
    InterventionInternal Radiation Therapy; Bicalutamide; Leuprolide Acetate; Goserelin Acetate +4 more
    PhaseNot applicable
    Registry statusCompleted

  • A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy

    NCT02159690 · start 2014-09

    Registered record
    Registry ID
    NCT02159690
    Conditions
    Prostate Cancer; Localized Prostate Cancer
    Interventions
    Enzalutamide; Abiraterone acetate; Prednisone; Dutasteride; Degarelix
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2014-09
    Completion
    2015-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Localized Prostate Cancer
    InterventionEnzalutamide; Abiraterone acetate; Prednisone; Dutasteride +1 more
    PhasePhase 2
    Registry statusWithdrawn

  • Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

    NCT01786265 · start 2013-02-05

    Registered record
    Registry ID
    NCT01786265
    Conditions
    Prostate Adenocarcinoma; Recurrent Prostate Carcinoma
    Interventions
    Abiraterone Acetate; Bicalutamide; Degarelix; Flutamide; Goserelin Acetate; Leuprolide Acetate; Nilutamide; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2013-02-05
    Completion
    2027-02-01
    Enrolment
    310

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Adenocarcinoma; Recurrent Prostate Carcinoma
    InterventionAbiraterone Acetate; Bicalutamide; Degarelix; Flutamide +4 more
    PhasePhase 2
    Registry statusActive not recruiting

  • A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer

    NCT01696877 · start 2013-01-18

    Registered record
    Registry ID
    NCT01696877
    Conditions
    Prostate Cancer Adenocarcinoma in Situ
    Interventions
    degarelix acetate; Cyclophosphamide; GVAX
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2013-01-18
    Completion
    2018-12-18
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer Adenocarcinoma in Situ
    Interventiondegarelix acetate; Cyclophosphamide; GVAX
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy

    NCT01751451 · start 2012-12-18

    Registered record
    Registry ID
    NCT01751451
    Conditions
    Prostate Cancer
    Interventions
    Abiraterone acetate; Abiraterone acetate plus degarelix; Degarelix
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-12-18
    Completion
    2020-09-28
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionAbiraterone acetate; Abiraterone acetate plus degarelix; Degarelix
    PhasePhase 2
    Registry statusCompleted

  • Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

    NCT01746849 · start 2012-12

    Registered record
    Registry ID
    NCT01746849
    Conditions
    Leukemia; Multiple Myeloma; Myelodysplastic Syndrome; Non-Hodgkin's Lymphoma
    Interventions
    Palifermin; Lupron; peripheral blood stem cell transplantation; Total-Body Irradiation (TBI); Thiotepa; Cyclophosphamide; Degarelix
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2012-12
    Completion
    2026-12
    Enrolment
    82

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia; Multiple Myeloma; Myelodysplastic Syndrome; Non-Hodgkin's Lymphoma
    InterventionPalifermin; Lupron; peripheral blood stem cell transplantation; Total-Body Irradiation (TBI) +3 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Degarelix in the Treatment of Endometriosis Recurrence

    NCT01712763 · start 2012-11

    Registered record
    Registry ID
    NCT01712763
    Conditions
    Endometriosis
    Interventions
    degarelix; Leuprolide Acetate 11.25 MG/ML (Enantone 11,25)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-11
    Completion
    2016-03
    Enrolment
    360

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis
    Interventiondegarelix; Leuprolide Acetate 11.25 MG/ML (Enantone 11,25)
    PhasePhase 3
    Registry statusCompleted

  • Ipilimumab + Androgen Depravation Therapy in Prostate Cancer

    NCT01377389 · start 2011-06-17

    Registered record
    Registry ID
    NCT01377389
    Conditions
    Prostate Cancer
    Interventions
    Ipilimumab; Leuprolide; Goserelin; Degarelix
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2011-06-17
    Completion
    2017-04-07
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionIpilimumab; Leuprolide; Goserelin; Degarelix
    PhasePhase 2
    Registry statusTerminated

  • Initiation of Androgen Deprivation Therapy for Prostate Cancer Using Degarelix Followed by Leuprolide

    NCT01344564 · start 2011-04

    Registered record
    Registry ID
    NCT01344564
    Conditions
    Prostate Cancer
    Interventions
    Degarelix acetate, Leuprolide acetate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2011-04
    Completion
    2012-08
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionDegarelix acetate, Leuprolide acetate
    PhaseNot applicable
    Registry statusCompleted